Bausch + Lomb Aktie

At the request of Bausch Health, Bausch + Lomb appointed four new members to its board and had the previous members step down; the appointments include executives and investors. In the second quarter, sales rose to $1.394 billion (reported +9%, currency-adjusted +8%) and operating cash flow increased to $153 million. The company affirmed its raised 2026 revenue guidance of $5.440–5.540 billion and adjusted EBITDA before acquired R&D of $1.025–1.075 billion, and points to an active product pipeline in eye health, surgical technologies, contact lenses, retinal diseases and applications of AI and computational biology. » More on de.investing.com

Bausch + Lomb’s stock climbed 2.3% pre-market after Q2 results: revenue $1.39bn (consensus $1.37bn, +9% YoY), adjusted EPS $0.15 in line with estimates. The company raised its 2026 revenue forecast to $5.44–5.54bn; operating income swung from -$11m to +$83m, operating cash flow rose to $153m and adjusted EBITDA to $241m. UBS initiated coverage with a buy recommendation; investors view the numbers as confirmation of the operational turnaround. » More on de.investing.com

Bausch + Lomb has introduced the preloaded IOL injector system EyeGility in the US for the enVista product family. The one‑handed system enables implantations through a 2.4‑mm incision, features an injection plunger with a soft silicone tip and a standby time of up to 20 minutes. EyeGility is currently available for enVista Aspire IOLs; preloaded enVista Envy lenses are expected to follow in coming months. The company warns of damage and injury risks if used with non‑cleared IOL models and recommends storage at room temperature below 43 °C. » More on de.investing.com